[Biologic agents for the treatment of psoriasis]

Secco A, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L
Record ID 32015000862
Authors' recomendations: There is high methodological quality evidence on the short-term efficacy of biologic agent therapy in patients with moderate to severe plaque psoriasis with inadequate response to systemic therapy, phototherapy or contraindication for any of the latter. Just one randomized clinical trial conducting direct comparisons and others based on indirect comparisons as well as health technology assessments suggest that infliximab would be the most effective agent during the treatment induction stage. Long-term evidence on the efficacy of biologic agent therapy versus both placebo and other systemic agents or phototherapy is scarce and heterogeneous. Clinical practice guidelines as well as several coverage policies agree on recommending the use of biologic agents in this group of patients.
Project Status: Completed
Year Published: 2015
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Psoriasis
  • Biological Products
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.